NAV

Phthalylsulfathiazole

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Phthalylsulfathiazole is a sulfonamide antibacterial indicated in the treatment of gastrointestinal infections.

Generic Name
Phthalylsulfathiazole
DrugBank Accession Number
DB13248
Background

Phthalylsulfathiazole is a broad spectrum antibiotic which is part of the drug class, sulfonamides. It was used as an antibiotic for bowel surgery, and for infections of the colon 1.

Type
Small Molecule
Groups
Approved
Structure
3D
Similar Structures
Weight
Average: 403.43
Monoisotopic: 403.029662879
Chemical Formula
C17H13N3O5S2
Synonyms
  • Phthalylsulfathiazole
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to treatDiarrheaCombination Product in combination with: Metronidazole (DB00916), Furazolidone (DB00614)••••••••••••••••••
Used in combination to treatDysenteryCombination Product in combination with: Kaolin (DB01575), Neomycin (DB00994), Furazolidone (DB00614), Diiodohydroxyquinoline (DB09115)••••••••••••••••••
Used in combination to treatEnteritisCombination Product in combination with: Kaolin (DB01575), Neomycin (DB00994), Diiodohydroxyquinoline (DB09115), Furazolidone (DB00614)••••••••••••••••••
Used in combination to treatGastrointestinal infectionsCombination Product in combination with: Kaolin (DB01575), Furazolidone (DB00614), Diiodohydroxyquinoline (DB09115), Neomycin (DB00994)••••••••••••••••••
Used in combination to treatInflammatory bowel diseases (ibd)Combination Product in combination with: Furazolidone (DB00614), Metronidazole (DB00916)••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Phthalylsulfathiazole.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be increased when used in combination with Phthalylsulfathiazole.
AlbiglutideThe therapeutic efficacy of Albiglutide can be increased when used in combination with Phthalylsulfathiazole.
AlogliptinThe therapeutic efficacy of Alogliptin can be increased when used in combination with Phthalylsulfathiazole.
BenzylpenicillinPhthalylsulfathiazole may decrease the excretion rate of Benzylpenicillin which could result in a higher serum level.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ไดฟูลินPhthalylsulfathiazole (250 mg) + Diiodohydroxyquinoline (250 mg) + Furazolidone (50 mg) + Kaolin (250 mg) + Neomycin sulfate (50 mg)Tabletบริษัท เอเชี่ยนยูเนี่ยนแล็บบอราตอรี่ จำกัด จำกัด1988-12-072020-07-19Thailand flag
ไดเซนโตPhthalylsulfathiazole (250 MG) + Diiodohydroxyquinoline (250 MG) + Furazolidone (50 MG) + Kaolin (250 MG) + Neomycin (50 MG)Tabletบริษัท แอดวานซ์ ฟาร์มาซูติคอล แมนูเฟคเจอริ่ง จำกัด2013-11-08Not applicableThailand flag

Categories

ATC Codes
G01AE10 — Combinations of sulfonamidesA07AB02 — Phthalylsulfathiazole
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Benzanilides
Alternative Parents
Benzenesulfonamides / Benzamides / Benzenesulfonyl compounds / Benzoic acids / Benzoyl derivatives / Organosulfonamides / Thiazoles / Aminosulfonyl compounds / Heteroaromatic compounds / Secondary carboxylic acid amides
show 8 more
Substituents
Aminosulfonyl compound / Aromatic heteromonocyclic compound / Azacycle / Azole / Benzamide / Benzanilide / Benzenesulfonamide / Benzenesulfonyl group / Benzoic acid / Benzoic acid or derivatives
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
sulfonamide, 1,3-thiazole, dicarboxylic acid monoamide (CHEBI:9336)
Affected organisms
Not Available

Chemical Identifiers

UNII
6875L5852V
CAS number
85-73-4
InChI Key
PBMSWVPMRUJMPE-UHFFFAOYSA-N
InChI
InChI=1S/C17H13N3O5S2/c21-15(13-3-1-2-4-14(13)16(22)23)19-11-5-7-12(8-6-11)27(24,25)20-17-18-9-10-26-17/h1-10H,(H,18,20)(H,19,21)(H,22,23)
IUPAC Name
2-({4-[(1,3-thiazol-2-yl)sulfamoyl]phenyl}carbamoyl)benzoic acid
SMILES
OC(=O)C1=CC=CC=C1C(=O)NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1

References

General References
  1. STREICHER MH: Phthalylsulfathiazole (sulfathialidine); clinical, chemical and bacteriologic evaluations in infectious diseases of the colon. J Am Med Assoc. 1945 Dec 15;129:1080-3. [Article]
  2. FDA Thailand: Dichlorrhea (Furazolidone, Metronidazole, and Phthalylsulfathiazole) Oral Tablet [Link]
KEGG Compound
C07659
ChemSpider
4641
RxNav
33632
ChEBI
9336
ChEMBL
CHEMBL1524273
ZINC
ZINC000001530877
Wikipedia
Phthalylsulfathiazole

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet
Tablet
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0171 mg/mLALOGPS
logP2.22ALOGPS
logP2.55Chemaxon
logS-4.4ALOGPS
pKa (Strongest Acidic)2.91Chemaxon
pKa (Strongest Basic)0.59Chemaxon
Physiological Charge-2Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area125.46 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity100.36 m3·mol-1Chemaxon
Polarizability37.83 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-052b-3940000000-92fc3db27cdfa654a5fd
MS/MS Spectrum - , positiveLC-MS/MSsplash10-052b-3940000000-92fc3db27cdfa654a5fd
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0f7a-0609600000-ea02dc59d68821ce714e
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0039000000-e4cde571ce1ccd0ce6d6
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0009100000-2b2bb1964d6f857e9929
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0pba-5349000000-1288b2c681d3ab7e1fd2
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0901000000-28444f09a912cc150b76
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004j-5912000000-8713db4cef11a2591ca8
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-209.1014835
predicted
DarkChem Lite v0.1.0
[M-H]-185.16881
predicted
DeepCCS 1.0 (2019)
[M+H]+209.7921835
predicted
DarkChem Lite v0.1.0
[M+H]+187.64986
predicted
DeepCCS 1.0 (2019)
[M+Na]+195.30252
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:38 / Updated at June 05, 2021 09:13